Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
Global analysis of impact of maintenance on survival after ASCT for myeloma regardless of response concludes in 6-month landmark analysis, OS 3 years higher w/ len (86%), thal (80%) & bortezomib (83%) vs. no maintenance.”
Title: Impact of maintenance therapy on survival after autologous stem cell transplant for multiple myeloma regardless of response: a global analysis
Authors: Andrew J. Cowan, Luuk Gras, Raffaella Cassano, Yoshiko Atsuta, Laurien Baaij, Francisca Bass, Ali Bazarbachi, Mohamed Amine Bekadja, Katherine Clesham, Peter Dreger, Anita D’Souza, Noel Estrada-Merly, Ai Sim Goh, Minako Iida, Patrick J. Hayden, Koji Kawamura, Bor-Sheng Ko, Linda Koster, Christopher Liam, Hira Mian, Arleigh McCurdy, Cristobal Augusto Frutos Ortiz, Nada Hamad, Donal P. McLornan, Meng Lv, Shohei Mizuno, Aloks Srivastava, Asmaa Quessar, Eloisa Riva, Wael Saber, John Snowden, Hiroyuki Takamatsu, Xavier Cheng-Hong Tsai, Estelle Verburgh, Ho Kim Wah, Daniel Neumann, Anna Sureda, Mahmoud Aljurf, Mickey Boon Chai Koh, Sebastian Galeano, Yoshihisa Kodera, Damiano Rondelli, Dietger W. Niederwieser, Laurent Garderet
You can read the full article on Haematologica.
You can find other articles featuring Robert Orlowski on OncoDaily.
